Alemtuzumab Therapy for Multiple Sclerosis

Neurotherapeutics

Volumn 10, Issue 1, 2013, Pages 29-33

  Coles, Alasdair J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alemtuzumab; Antibody; Autoimmunity; Disability; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB;

AUTOIMMUNITY; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RASH; REVIEW;

EID: 84873150369     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0159-0     Document Type: Review

References (28)

1. Riechmann L, et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
3. Waldmann H, Hale G. CAMPATH: from concept to clinic. Phil Trans Roy Soc Lond B Biol Sci 2005; 360: 1707-1711.
4. Lockwood CM, et al. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003; 42: 1539-1544.
5. Dick AD, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000; 84: 107-109.
6. Isaacs JD, et al. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 1995; 79: 1054-1055.
7. Isaacs JD, et al. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 1996; 23: 1103-1106.
8. Isaacs JD, et al. CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J Rheumatol 1996; 35: 231-240.
9. Newman DK, et al. Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody. CAMPATH-1H. Eye (Lond) 1995; 9(pt 5): 564-569.
10. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137-143.
11. Xia MQ, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293(pt 3): 633-640.
12. Xia MQ, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991; 21: 1677-1684.
13. Hu Y, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 260-270.
14. Wing MG, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98: 2819-2826.
15. Moreau T, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119(pt 1): 225-237.
16. Hill-Cawthorne GA, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
17. Cox AL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 3332-3342.
18. Thompson SA, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis. J Clin Immunol 2009; 99-105.
19. Kurtzke JF. Rating neurologic impairment in multiple-sclerosis - an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
20. Coles AJ, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
21. Coles AJ, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
22. Coles AJ, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology 2012; 1069-78.
23. Berker D, et al. Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism. Endocrine 2011; 39: 13-20.
24. Somerfield J, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010; 185: 763-768.
25. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008; 359: 768-769.
26. Hsiao LT, et al. Relapse of Graves' disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1151-1153.
27. Gilquin J, et al. Delayed occurrence of Graves' disease after immune restoration with HAART. Lancet 1998; 352: 1907-1908.
28. Jones JL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-2061.